Bard Financial Services Inc. Sells 214 Shares of Johnson & Johnson (NYSE:JNJ)

Bard Financial Services Inc. cut its position in Johnson & Johnson (NYSE:JNJ) by 0.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 100,028 shares of the company’s stock after selling 214 shares during the quarter. Johnson & Johnson makes up 1.7% of Bard Financial Services Inc.’s investment portfolio, making the stock its 8th biggest holding. Bard Financial Services Inc.’s holdings in Johnson & Johnson were worth $14,466,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in JNJ. Denver PWM LLC purchased a new position in Johnson & Johnson in the 2nd quarter valued at $62,000. VELA Investment Management LLC lifted its stake in shares of Johnson & Johnson by 212.4% in the second quarter. VELA Investment Management LLC now owns 31,434 shares of the company’s stock valued at $4,594,000 after purchasing an additional 21,371 shares during the period. Arizona State Retirement System grew its position in Johnson & Johnson by 1.1% during the second quarter. Arizona State Retirement System now owns 698,610 shares of the company’s stock worth $102,109,000 after buying an additional 7,801 shares during the period. Jeppson Wealth Management LLC lifted its position in shares of Johnson & Johnson by 16.6% during the 2nd quarter. Jeppson Wealth Management LLC now owns 14,082 shares of the company’s stock valued at $2,058,000 after acquiring an additional 2,005 shares during the period. Finally, Foundry Partners LLC boosted its stake in shares of Johnson & Johnson by 34.0% during the 2nd quarter. Foundry Partners LLC now owns 207,450 shares of the company’s stock worth $30,321,000 after acquiring an additional 52,585 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Analysts Set New Price Targets

JNJ has been the topic of a number of research analyst reports. Wells Fargo & Company boosted their target price on Johnson & Johnson from $163.00 to $166.00 and gave the stock an “equal weight” rating in a research report on Wednesday, October 16th. Guggenheim upped their price target on shares of Johnson & Johnson from $156.00 to $162.00 and gave the company a “neutral” rating in a report on Wednesday, November 6th. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday, September 14th. Wolfe Research assumed coverage on Johnson & Johnson in a report on Friday, November 15th. They issued an “outperform” rating and a $190.00 price target for the company. Finally, Bank of America reaffirmed a “neutral” rating and set a $166.00 price target on shares of Johnson & Johnson in a research note on Tuesday, December 10th. Seven research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $174.71.

Johnson & Johnson Stock Down 0.2 %

Shares of NYSE JNJ traded down $0.22 on Monday, hitting $143.97. The company had a trading volume of 3,573,790 shares, compared to its average volume of 5,087,375. The firm has a market capitalization of $346.63 billion, a P/E ratio of 20.84, a PEG ratio of 2.52 and a beta of 0.51. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45. Johnson & Johnson has a 12-month low of $142.75 and a 12-month high of $168.85. The business has a 50 day moving average of $151.40 and a two-hundred day moving average of $156.28.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share for the quarter, beating analysts’ consensus estimates of $2.21 by $0.21. The business had revenue of $22.47 billion during the quarter, compared to analyst estimates of $22.17 billion. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. The business’s revenue was up 5.2% on a year-over-year basis. During the same period last year, the business earned $2.66 EPS. As a group, equities research analysts forecast that Johnson & Johnson will post 9.94 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be paid a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a dividend yield of 3.45%. The ex-dividend date is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 71.78%.

Insider Transactions at Johnson & Johnson

In other news, Director Mark A. Weinberger acquired 1,000 shares of the stock in a transaction that occurred on Thursday, December 12th. The stock was purchased at an average cost of $147.22 per share, with a total value of $147,220.00. Following the completion of the acquisition, the director now directly owns 1,000 shares in the company, valued at $147,220. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.